Human Rabies Vaccines Market Report

Rising prevalence of rabies is increasing globally and leading to the growth of the human rabies vaccine market. Recently on 5 June 2024, the WHO (World Health Organization) estimated that, globally there are 59,000 deaths from rabies annually; however, due to underreporting, the number of documented cases often differ from the estimate. International collaborations and governmental support foster research and development, encouraging the production of efficacious and affordable vaccines. Public awareness campaigns regarding rabies prevention reinforce the demand for vaccines, promoting their use and distribution to ensure human health and help reduce the global burden of rabies.

The development of new and more efficient rabies vaccination by using recombinant and cell cultures has significantly driven the growth of the human vaccine market. Rabies is a viral disease, thus there is an increased chance of contracting rabies by increased travel and exposure to rabies-prone areas. This results in increased demand for pre-exposure prophylaxis among travelers. Advancements in biotechnology and new vaccine technologies make human rabies vaccines more effective whereas, improved vaccine formulation and advanced adjuvant and delivery methods result in improvement of vaccine efficacy.

The pre-expose vaccine is recommended for individuals at high risk of exposure to rabies, while the post-exposure vaccine is administrated to individuals who have been bitten or scratched by an animal suspected of rabies. These two types of vaccines control the spread of disease and help to prevent the inception of rabies in humans. Human rabies vaccines are developed by using various types of cell lines including chick embryo cell-based vaccines, Vero cells vaccines and BHK cells vaccines. Multiplicity in cell types used for vaccine production enables manufacturers to develop different types of vaccines, to meet the needs of different regions.

Increasing healthcare expenditure by several organizations leads to the expansion of the human rabies vaccines market. Evolving developments in technology and medicine have developed new vaccine manufacturing methods with a broad knowledge of immunology, biochemistry, and molecular biology among other basic science disciplines, which may assist vaccine manufacturers in understanding the disease and develop new adjuvants for prevention of diseases.

• Human rabies vaccines without live or inactivated rabies virus components using recombinant DNA technology.
• Immunization campaigns by government and healthcare organizations.
• Development of effective adjuvants to boost vaccine efficacy.
• Advancements in vaccine delivery methods and technologies.
• Cell culture technology to produce human rabies vaccines.

Human rabies vaccines can be expensive, especially cell-mediated vaccines which can be a significant barrier in less economically developed countries. The complex approval process of vaccines and extensive clinical trials pose a challenge for vaccine manufacturers, leading to delay in product launches. Research and development, clinical trials and regulatory approvals needs extensive investments to develop and manufacture vaccines. High development costs can limit innovation in vaccine technologies and may hamper the growth of the human rabies market. Apart from this, in less economically developed countries, a lack of awareness about the prevention of rabies and the significance of vaccination remains a considerable challenge. Also delay in diagnosis of rabies leads to delay in treatment initiation. Thus, government campaigns are crucial for the expansion of market growth.

Researchers are constantly aiming to explore and develop new vaccine formulations that offer improved immune response against rabies with fewer doses and potentially reduce side effects. Intradermal injection administration has gained attention due to its potential to reduce vaccine doses and increase in cost-effectiveness. Thermostable rabies vaccines are developed to remain efficacious at higher temperatures due to the challenge of maintaining cold chain requirements which can reduce costs associated with refrigeration and transportation.

On 13 June 2024, WHO (World Health Organization) informed that Gavi collaborates with partners to support human rabies vaccines for post-exposure prophylaxis (PEP) as a part of routine immunization. Addressing developments in the human rabies vaccine, researchers at Uniformed Services University (USU) had made a significant innovation against the viral infection rabies in September 2023. F11 monoclonal antibody proven to be more efficacious and successful cure for human rabies and it is believed to work primarily through neutralization which binds to the virus and prevents infection of cells and tissues.

Asia-Pacific is experiencing rapid growth due to the large populations base and increasing healthcare expenditure with a high prevalence of rabies cases due to the massive stray dog population in countries such as India and China. Education and awareness campaigns about prevention of human rabies vaccines organized by government and organizations are playing a crucial role in driving human rabies vaccines market. Also, these countries host several manufacturers of rabies vaccines, producing both pre & and post-exposure vaccine.

The Middle East and Africa region are heavily exposed to the prevalence of rabies, thus to prevent the spread of rabies the demand for human rabies vaccine is driving the market in both pre & post-exposure therapies. rising prevalence of rabies in Latin America is experiencing human rabies vaccines market growth. This region has resulted in more pet ownership and interaction with wildlife, as a result the demand for pre-exposure prophylaxis and post-exposure therapies expanding the human rabies vaccines market.

The report provides a detailed overview of the human rabies vaccines market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for human rabies vaccines market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the human rabies vaccines market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the human rabies vaccines market. Some key country and region included in the human rabies vaccines market report as follows:

• Human rabies vaccines market detailed segments and segment-wise market breakdown
• Human rabies vaccines market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in human rabies vaccines industry)
• Current, historical and forthcoming 10 years market valuation in terms of human rabies vaccines market size (US$ Mn), volume (Units), share (%), Y-o-Y growth rate, CAGR (%) analysis
• Human rabies vaccines market demand analysis
• Human rabies vaccines market pricing analysis over forecast period (by key segment and by region)
• Human rabies vaccines market regional insights with region-wise market breakdown
• Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
• Latest developments and innovations in human rabies vaccines market
• Regulatory landscape by key regions and key countries
• Supply chain and value chain analysis in human rabies vaccines market
• Human rabies vaccines market sales and distribution strategies
• A comprehensive overview of parent market
• A detailed viewpoint on human rabies vaccines market forecast by countries
• Mergers and acquisitions in human rabies vaccines market
• Essential information to enhance market position
• Robust research methodology